Kroemer, Heyo Klaus

[["dc.bibliographiccitation.artnumber","144"],["dc.bibliographiccitation.journal","Journal of Translational Medicine"],["dc.bibliographiccitation.volume","12"],["dc.contributor.author","Grabe, Hans Joergen"],["dc.contributor.author","Assel, Heinrich"],["dc.contributor.author","Bahls, Thomas"],["dc.contributor.author","Doerr, Marcus"],["dc.contributor.author","Endlich, Karlhans"],["dc.contributor.author","Endlich, Nicole"],["dc.contributor.author","Erdmann, Pia"],["dc.contributor.author","Ewert, Ralf"],["dc.contributor.author","Felix, Stephan B."],["dc.contributor.author","Fiene, Beate"],["dc.contributor.author","Fischer, Tobias"],["dc.contributor.author","Flessa, Steffen"],["dc.contributor.author","Friedrich, Nele"],["dc.contributor.author","Gadebusch-Bondio, Mariacarla"],["dc.contributor.author","Salazar, Manuela Gesell"],["dc.contributor.author","Hammer, Elke"],["dc.contributor.author","Haring, Robin"],["dc.contributor.author","Havemann, Christoph"],["dc.contributor.author","Hecker, Michael"],["dc.contributor.author","Hoffmann, Wolfgang"],["dc.contributor.author","Holtfreter, Birte"],["dc.contributor.author","Kacprowski, Tim"],["dc.contributor.author","Klein, Kathleen"],["dc.contributor.author","Kocher, Thomas"],["dc.contributor.author","Kock, Holger"],["dc.contributor.author","Krafczyk, Janina"],["dc.contributor.author","Kuhn, Jana"],["dc.contributor.author","Langanke, Martin"],["dc.contributor.author","Lendeckel, Uwe"],["dc.contributor.author","Lerch, Markus M."],["dc.contributor.author","Lieb, Wolfgang"],["dc.contributor.author","Lorbeer, Roberto"],["dc.contributor.author","Mayerle, Julia"],["dc.contributor.author","Meissner, Konrad"],["dc.contributor.author","Schwabedissen, Henriette E. Meyer zu"],["dc.contributor.author","Nauck, Matthias"],["dc.contributor.author","Ott, Konrad"],["dc.contributor.author","Rathmann, Wolfgang"],["dc.contributor.author","Rettig, Rainer"],["dc.contributor.author","Richardt, Claudia"],["dc.contributor.author","Salje, Karen"],["dc.contributor.author","Schminke, Ulf"],["dc.contributor.author","Schulz, Andrea"],["dc.contributor.author","Schwab, Matthias"],["dc.contributor.author","Siegmund, Werner"],["dc.contributor.author","Stracke, Sylvia"],["dc.contributor.author","Suhre, Karsten"],["dc.contributor.author","Ueffing, Marius"],["dc.contributor.author","Ungerer, Saskia"],["dc.contributor.author","Voelker, Uwe"],["dc.contributor.author","Voelzke, Henry"],["dc.contributor.author","Wallaschofski, Henri"],["dc.contributor.author","Werner, Vivian"],["dc.contributor.author","Zygmunt, Marek T."],["dc.contributor.author","Kroemer, Heyo K."],["dc.date.accessioned","2018-11-07T09:39:59Z"],["dc.date.available","2018-11-07T09:39:59Z"],["dc.date.issued","2014"],["dc.description.abstract","Background: Individualized Medicine aims at providing optimal treatment for an individual patient at a given time based on his specific genetic and molecular characteristics. This requires excellent clinical stratification of patients as well as the availability of genomic data and biomarkers as prerequisites for the development of novel diagnostic tools and therapeutic strategies. The University Medicine Greifswald, Germany, has launched the \"Greifswald Approach to Individualized Medicine\" (GANI_MED) project to address major challenges of Individualized Medicine. Herein, we describe the implementation of the scientific and clinical infrastructure that allows future translation of findings relevant to Individualized Medicine into clinical practice. Methods/design: Clinical patient cohorts (N > 5,000) with an emphasis on metabolic and cardiovascular diseases are being established following a standardized protocol for the assessment of medical history, laboratory biomarkers, and the collection of various biosamples for bio-banking purposes. A multi-omics based biomarker assessment including genome-wide genotyping, transcriptome, metabolome, and proteome analyses complements the multi-level approach of GANI_MED. Comparisons with the general background population as characterized by our Study of Health in Pomerania (SHIP) are performed. A central data management structure has been implemented to capture and integrate all relevant clinical data for research purposes. Ethical research projects on informed consent procedures, reporting of incidental findings, and economic evaluations were launched in parallel."],["dc.identifier.doi","10.1186/1479-5876-12-144"],["dc.identifier.isi","000338469800002"],["dc.identifier.pmid","24886498"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/10153"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/33415"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.relation.issn","1479-5876"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Cohort profile: Greifswald approach to individualized medicine (GANI_MED)"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","688"],["dc.bibliographiccitation.firstpage","1"],["dc.bibliographiccitation.issue","688"],["dc.bibliographiccitation.journal","BMC Research Notes"],["dc.bibliographiccitation.lastpage","6"],["dc.bibliographiccitation.volume","7"],["dc.contributor.author","Meyer zu Schwabedissen, Henriette Elisabeth"],["dc.contributor.author","Siegmund, Werner"],["dc.contributor.author","Kroemer, Heyo Klaus"],["dc.contributor.author","Rollnik, Jens D."],["dc.date.accessioned","2019-04-30T12:38:18Z"],["dc.date.available","2019-04-30T12:38:18Z"],["dc.date.issued","2014"],["dc.description.abstract","BACKGROUND: Genetic factors as predictor of the individual outcome of drug therapy is one aim of personalized medicine approaches. CASE PRESENTATION: We report a drug metabolism based analysis of genetic polymorphisms in a Caucasian patient receiving fluvastatin and telmisartan experiencing myotoxicity (myalgia and moderate creatine kinase elevation). CONCLUSIONS: The obtained findings suggest that heterocygocity of cytochrome P450 CYP2C9 3 variant in combination with multidrug resistance-associated protein MRP2-24C > T functions as risk factor predisposing to experience drug-drug interaction combing those drugs."],["dc.identifier.doi","10.1186/1756-0500-7-688"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/10966"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/57892"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","final"],["dc.relation.eissn","1756-0500"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Creatine kinase elevation caused by a combination of fluvastatin and telmisartan in a patient heterozygous for the CYP2C9 3 and ABCC2 -24C T variants: a case report"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]